What Are GLP-1 Medications?

GLP-1 receptor agonists mimic a natural hormone released by the gut after eating. They:

• Increase glucose-dependent insulin secretion

• Decrease glucagon secretion

• Slow gastric emptying

• Increase satiety and reduce appetite

Key Benefits of GLP-1 Medications

1. Significant and Sustained Weight Loss

GLP-1 medications are among the most effective non-surgical treatments for obesity.

Clinical trials show:

• Average weight loss ranging from approximately 5% to over 20%, depending on the agent and dose

• Greater weight loss compared to older anti-obesity medications

• Sustained weight reduction when therapy is continued

2. Improved Blood Sugar Control

For patients with type 2 diabetes:

• A1c reductions of approximately 1–2%

• Low risk of hypoglycemia when used alone

• Effective as first-line injectable therapy before insulin in many patients

3. Cardiovascular Protection

Certain GLP-1 medications:

• Reduce major adverse cardiovascular events (heart attack, stroke, cardiovascular death)

• Improve blood pressure

• Improve lipid profiles

• Reduce inflammation and atherosclerotic risk

4. Kidney Protection

GLP-1 medications:

• Reduce albuminuria

• Slow progression of diabetic kidney disease

• Provide benefit in patients with chronic kidney disease

5. Improvement in Metabolic Syndrome

GLP-1 therapy improves multiple cardiometabolic parameters:

• Decreased waist circumference

• Reduced triglycerides

• Improved HDL and LDL profiles

• Lower blood pressure

• Improved insulin resistance

6. Benefit in Fatty Liver Disease

Emerging evidence shows improvement in metabolic dysfunction-associated steatotic liver disease (formerly NAFLD), liver inflammation, and hepatic fat content.

7. PCOS Management: A Transformative Application

Polycystic ovary syndrome (PCOS) affects 6–20% of women of reproductive age and is a leading cause of infertility. GLP-1 medications are emerging as a game-changing therapy for this condition.

Why GLP-1s Help in PCOS:

Metabolic Benefits:

• Significant weight reduction (5–15% or more), which is often sufficient to restore ovulation in PCOS patients Ther Adv Endocrinol

• Improved insulin sensitivity and reduced fasting glucose Ther Adv Endocrinol

• Decreased visceral and liver fat Ther Adv Endocrinol

• Improved lipid profiles and cardiovascular markers Ther Adv Endocrinol

Reproductive Benefits:

• Improved menstrual regularity: Studies show 58–62% of women experience restored menstrual cycles Ther Adv Endocrinol

• Reduced androgen levels: Decreases in free testosterone, androstenedione, and free androgen index Ther Adv Endocrinol +1Diabet Obes Met

• Enhanced ovulation rates: Exenatide combined with metformin achieved 86% ovulation rates versus 29% with metformin alone Ther Adv Endocrinol

• Increased fertility: Natural pregnancy rates improved to 43.6% with exenatide versus 18.7% with metformin alone Ther Adv Endocrinol

• IVF success: Liraglutide plus metformin increased pregnancy rate per embryo transfer to 85.7% versus 28.6% with metformin alone Ther Adv Endocrinol

Mechanism Beyond Weight Loss:
Research suggests GLP-1s may directly influence the hypothalamic-pituitary-gonadal axis, increasing LH surge and improving ovarian function independent of weight loss effects Ther Adv Endocrinol

Evidence-Based Recommendations:

GuidelineRecommendation2023 International PCOS Guideline Eur J EndocrinolAnti-obesity medications including liraglutide and semaglutide could be considered for management of higher weight in adults with PCOSAACE/ACE GuidelinesConsider liraglutide, metformin, or orlistat for weight reduction and improving PCOS manifestations

Combination Therapy:

GLP-1 receptor agonists combined with metformin appear superior to either agent alone for:

• Weight and BMI reduction

• Menstrual regularity

• Ovulation rates

• Metabolic parameters Diabet Obes Met

8. Heart Failure and Cardiometabolic Risk Reduction

GLP-1 medications have shown symptom improvement in certain heart failure populations and reduction in hospitalization risk in high-risk cardiometabolic patients.

9. Appetite Regulation and Behavioral Support

Because GLP-1 medications reduce food cravings and enhance satiety:

• Patients report improved control over eating

• Reduced binge or emotional eating

• Easier adherence to nutrition plans

Safety in Pregnancy and Breastfeeding: Evidence-Based Guidance

Current Evidence Summary

AspectFindingFDA StatusAll GLP-1 receptor agonists are contraindicated in pregnancy Diabetes Ther +1J Clin Endocr MetAnimal StudiesReproductive toxicity observed; early pregnancy losses and fetal abnormalities in animal studies exposed during organogenesis J Clin Endocr MetHuman DataLimited but growing; no consistent signal of increased congenital malformations in observational studies Diabet Obes MetLactationNot recommended — data extremely sparse; one pharmacokinetic study found no detectable semaglutide in human milk Diabet Obes Met

Key Safety Considerations

Before Conception:

• Discontinuation timing: Semaglutide requires stopping 2 months before pregnancy due to long half-life; other agents may require shorter intervals J Clin Endocr Met

• Weight gain risk: Discontinuation often results in rebound weight gain, which may complicate pregnancy metabolic management J Clin Endocr Met

• Contraception: Effective contraception is essential during treatment — the 2023 International PCOS Guideline emphasizes this practice point Eur J Endocrinol

Inadvertent First-Trimester Exposure:

A 2025 systematic review of 36 studies found Diabet Obes Met:

• No consistent association with major congenital malformations, fetal growth restriction, stillbirth, or neonatal mortality in adjusted analyses

• Maternal outcomes were heterogeneous without a reproducible safety signal

• However: Data on continued use throughout gestation remain limited

Case Reports in PCOS Patients:

• One PCOS patient using liraglutide throughout first trimester delivered healthy female infant at 37 weeks; transient neonatal hypoglycemia resolved within 24 hours Diabet Obes Met

• One PCOS patient using semaglutide until gestational week 3+4 delivered at 41+5 weeks; infant had shoulder dystocia and transient hypoglycemia but was healthy at 6 months Diabet Obes Met

Practical Recommendations:

ScenarioRecommendationPlanning pregnancyDiscontinue GLP-1 at least 2 months before conception (semaglutide); discuss transition to metformin or insulin as appropriateUnintentional pregnancy on GLP-1Discontinue immediately; consult OB/GYN and endocrinology; individualized risk assessmentBreastfeedingAvoid use; insufficient safety data; consider alternative agents with established lactation safety

Brief Overview of Contraindications and Cautions

Contraindications:

• Personal or family history of medullary thyroid carcinoma

• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

• Pregnancy or breastfeeding

• History of serious hypersensitivity reaction to the medication

Use With Caution:

• History of pancreatitis

• Severe gastroparesis

• Active gallbladder disease

• Proliferative diabetic retinopathy (certain agents)

• Advanced renal impairment (agent-specific considerations)

Common Side Effects:

• Nausea, vomiting

• Diarrhea or constipation

• Decreased appetite

• Injection site reactions

Most gastrointestinal side effects occur during dose escalation and improve over time.

The Bottom Line

GLP-1 medications are not just "weight loss shots." They are powerful, disease-modifying therapies that:

• Improve metabolic health

• Reduce cardiovascular risk

• Protect kidney function

• Support meaningful and sustained weight reduction

• Restore fertility and menstrual function in PCOS patients

When prescribed appropriately — with attention to contraception and preconception planning — they can significantly improve long-term health outcomes.

Mobile Wellness Services LLC
657-749-2427
mobilewellness23@gmail.com

Contact

Reach out anytime for personalized wellness support.

Phone: 657-749-2427 feel free to text us!

Email: MOBILEwellness23@gmail.com

© 2025. All rights reserved.